A Research Study to Assess the Mechanism By Which Glucovance, Metformin, and Glyburide Work To Control Glucose Levels In Patients With Type 2 Diabetes - Full Text View

A Research Study to Assess the Mechanism By Which Glucovance, Metformin, and Glyburide Work To Control Glucose Levels In Patients With Type 2 Diabetes

This study has been completed.

Sponsored by:	Bristol-Myers Squibb
Information provided by:	Bristol-Myers Squibb
ClinicalTrials.gov Identifier:	NCT00035568

Purpose

The purpose of this clinical research study is to support earlier observations that Glucovance controls glucose levels after a mean, and improves overall glucose control better than metformin or glyburide therapy alone in adults with type 2 diabetes.

Condition	Intervention	Phase
Diabetes Mellitus, Non-Insulin-Dependent	Drug: Glucovance (metformin HCl/glyburide) Drug: or Metformin HCl alone Drug: or Glyburide alone.	Phase IV

MedlinePlus related topics:

Diabetes

Drug Information available for:

Glyburide Metformin Metformin hydrochloride Dextrose Glucovance

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment

Eligibility

Ages Eligible for Study:	20 Years to 75 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Adults 20-75 with a diagnosis of type 2 diabetes mellitus who are not adequately controlled with diet and exercise, and have an HbA1c greater than 6.7%

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00035568

Locations


United States, Arkansas
	Local Institution
	Little Rock, Arkansas, United States

United States, California
	Local Institution
	Los Angeles, California, United States

United States, Illinois
	Local Institution
	Chicago, Illinois, United States

United States, Indiana
	Local Institution
	Indianapolis, Indiana, United States

United States, New York
	Local Institution
	Brooklyn, New York, United States
	Local Institution
	Rochester, New York, United States

United States, Pennsylvania
	Local Institution
	Pittsburgh, Pennsylvania, United States

United States, Texas
	Local Institution
	Dallas, Texas, United States
	Local Institution
	San Antonio, Texas, United States

Sponsors and Collaborators

Bristol-Myers Squibb

More Information

BMS Clinical Trials Disclosure This link exits the ClinicalTrials.gov site

For FDA Safety Alerts and Recalls refer to the following link www.fda.gov/MEDWATCH/safety.htm This link exits the ClinicalTrials.gov site

Study ID Numbers:	CV138-062
First Received:	May 3, 2002
Last Updated:	September 27, 2007
ClinicalTrials.gov Identifier:	NCT00035568
Health Authority:	United States: Food and Drug Administration